Creative Biolabs Launches Innovative OMV and Exosome Platform for Advanced Solid Tumor CAR-T

Creative Biolabs has officially launched a next-generation, integrated OMV and exosome-boosted CAR-T development platform specifically designed to overcome the persistent challenges associated with solid tumor immunotherapy. By utilizing a dual-vesicle engineering strategy, the platform addresses critical barriers such as poor T-cell infiltration, metabolic exhaustion, and the complex, immunosuppressive nature of the tumor microenvironment. This sophisticated approach enables researchers to combine multiple therapeutic modalities into a single, cohesive research pipeline.

The platform distinguishes itself by offering both bacterial outer membrane vesicles (OMVs) for stroma remodeling and mammalian-derived exosomes for sustaining T-cell persistence. Key innovations include the BROAD-CAR system for synthetic antigen redirection and specialized cargo loading capabilities for nucleic acids and proteins. These features allow for the localized delivery of checkpoint inhibitors and metabolic modulators, which are essential for enhancing the efficacy of CAR-T therapies in difficult-to-treat, heterogeneous tumor models.

Designed to provide a comprehensive toolkit for preclinical development, the platform supports researchers in navigating the safety and efficacy complexities of modern immunotherapy. With integrated workflows for pharmacokinetic profiling and antigen-independent targeting, Creative Biolabs is empowering scientists to accelerate the transition of novel solid tumor treatments from the lab to clinical validation. This milestone represents a significant step forward in the quest to broaden the scope of CAR-T cell applications.